Status:
COMPLETED
Study Investigating Administration of Prevenar for Post-Marketing Surveillance
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Pneumococcal Infections
Eligibility:
All Genders
6-9 years
Brief Summary
The purpose of this study is to identify the following problems and questions with respect to the safety of Pneumococcal 7-Valent Conjugate Vaccine (Diphtheria CRM 197 Protein), Prevenar, during the p...
Eligibility Criteria
Inclusion
- Infants and children aged 6 weeks to 9 years, provided the conditions pertaining to contraindications, warnings, precautions, and interactions stated in the package insert do not apply.
Exclusion
- Hypersensitivity to latex or to any component of the vaccine, including diphtheria toxoid
- Suffering from a current or recent febrile illness.
Key Trial Info
Start Date :
July 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2008
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00195390
Start Date
July 1 2004
End Date
July 1 2008
Last Update
September 25 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul, South Korea, 100-380